In people living with #Obesity, excess adiposity may lead to structural and #Cardiometabolic changes. That is how one disease is associated with the risk of developing more than 200 complications.¹ Follow us for more!

A big thank you to the research community for all the discussions at #SleepEurope2026. Follow us to stay connected on developments in #Obesity and its related complications.

As an official sponsor of #SleepEurope2026, Lilly is proud to bring scientific exchange to the forefront, focusing on managing #Obesity as a chronic, complex disease and its related complications.¹,² Join our symposium for HCPs and visit our booth.

Have you wondered what a day in the life of a person living with #Obesity-related complications feels like? Visit the Lilly Booth during #SleepEurope2026 to experience the patient journey firsthand, or follow us for updates!

If you are at #SleepEurope2026, join Lilly’s symposium for HCPs on managing patients with Obesity and Obesity-related complications. Hear expert insights on evolving #ObesityCare and moving beyond a one-size-fits-all approach.

#SleepEurope2026 is almost here! We're proud to show our commitment to #ESRS as we discuss Obesity-related complications, and why early #ObesityCare may prevent or reduce their risk.¹,² Follow us for updates.

According to the IMPACT-O study, diagnosis of overweight or #Obesity was often not documented in a person's medical records, which can lead to underestimation of the impact of overweight or Obesity, lower quality of life and missed opportunities.*

Early action matters in #ObesityCare.¹ #Obesity is a complex, chronic, progressive, and relapsing disease, but prompt intervention gives us the opportunity to alter its trajectory.¹⁻³

Thank you to the scientific community, attendees, and partners at #EASD2026. We enjoyed the conversations that will help shape the future of #Cardiometabolic care. The next step is looking ahead. Follow us to stay informed.

What is next for #Cardiometabolic care? Science doesn't pause when #EASD2026 ends. From early intervention to long-term protection, what we have learned continues to advance cardiometabolic care. Stay with us, follow what's next!

#Obesity is a chronic, progressive, biologically driven, and relapsing disease in which excess adipose tissue impairs overall health, causing a ripple effect linked to over 200 medical conditions.¹⁻³ Hear Prof. Rachel Batterham, OBE. explain the science at #EASD2026. Follow us!

To celebrate Lilly’s 150ᵗʰ anniversary, we have curated a memorable experience out in the streets of Milan. Hop on our iconic tram, watch Central Station lit up in Lilly’s Red, and follow our guided path through 150 years of care. Look for us outside the #EASD2026 congress walls!

Health is out there! We are bringing the #Cardiometabolic conversation outside #EASD2026. Spot our billboards across Milan this week and follow our account so you don’t miss our updates from the congress.

Our exhibition celebrates 150 years of scientific progress, reframing research through the lens of art and fashion. Step inside House of Lilly in Milan during #EASD2026 and discover tailored science. Join us!

Next destination? Lilly’s booth! Join us at our booth at #EASD2026 as we celebrate 150 years of scientific progress. We look forward to seeing you there!

Explore the multidisciplinary sides of #Obesity care in our 3-session video compilation. Hear Prof. Rachel Batterham dive into guidelines and watch two animations on acting earlier and reducing stigma to help rewrite Obesity care. Only at #EASD2026 - follow us and stay updated!

Is a paradigm shift required to achieve long-term weight management? Join us with Dr. Arya M. Sharma and Dr. Luc Van Gaal at #EASD2026. We will discuss why early action in weight management matters and how shifting the #Obesity care paradigm may help improve outcomes. Follow us!

#EASD2026 has officially begun! A week of scientific exchange starts with a welcome message from Prof. Rachel Batterham, live from Milan. Follow us to learn more about what’s helping to shape the future of #Cardiometabolic care.

The rising prevalence of #Obesity is a primary driver behind the exponential growth of #T2D.¹ Its complexity lies in how adipose tissue disrupts metabolic balance and insulin signaling.² Follow us for more insights.

For 150 years, science and care for people have guided our work. At #EASD2026, we continue to advance #Cardiometabolic health by deepening our understanding of how these interconnected conditions impact lives around the world. Follow us as we help to shape what's next!